Anti-infective therapy at end of life: Ethical decision-making in hospice-eligible patients

Bioethics

Volumn 19, Issue 4, 2005, Pages 379-392

  Ford, Paul J ^a   Fraser, Thomas G ^a   Davis, Mellar P ^a   Kodish, Eric ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT; PIPERACILLIN PLUS TAZOBACTAM; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; DIALYSIS; DYING; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPICE CARE; HUMAN; HYDRATION; HYPERCALCEMIA; INFECTION; LIFE EXPECTANCY; MEDICAL CARE; MEDICAL DECISION MAKING; MEDICAL ETHICS; NUTRITION; REVIEW;

DEATH AND EUTHANASIA; HEALTH CARE AND PUBLIC HEALTH;

ADULT; ANTI-INFECTIVE AGENTS; DECISION MAKING; DRUG COSTS; DRUG RESISTANCE, MICROBIAL; EVIDENCE-BASED MEDICINE; HOSPICE CARE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MEDICAL FUTILITY; NUTRITIONAL SUPPORT; PALLIATIVE CARE; PHYSICIAN-PATIENT RELATIONS; RENAL DIALYSIS; RISK ASSESSMENT; TERMINALLY ILL; WITHHOLDING TREATMENT;

EID: 23944455453     PISSN: 02699702     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-8519.2005.00450.x     Document Type: Review

References (34)

1. We purposely use 'anti-infective' to describe the broad class of treatments that include antibiotics, antivirals, and antifungals.
2. D. Oneschuk, R. Fainsinger & D. Demoissac. Antibiotic use in the last week of life in three different palliative care settings. J Palliat Care 2002; 18(1): 25-28.
3. P.H. White, H.L. Kuhlenschmidt, B.G. Vancura & R.M. Navari. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manage 2003; 25(5): 438-443.
4. Oneschuk, op. cit. note 2;
5. White, ibid.;
6. see also L. Vitetta, D. Kenner, A. Sali. Bacterial infections in terminally ill hospice patients. J Pain Symptom Manage 2000; 20(5): 326-334.;
7. L.K. Chen, Y.C. Chou, P.S. Hsu, S.T. Tsai, S.J. Hwang, B.Y. Wu et al. Antibiotic prescription for fever episodes in hospice patients. Support Care Cancer 2002; 10(7): 538-541.
8. E.L. Marcus, A.M. Clarfield & A.E. Moses. Ethical issues relating to the use of antimicrobial therapy in older adults. Clin Infect Dis 2001; 33(10): 1697-1705;
9. J.P. Janssens & K.H. Krause. Pneumonia in the very old. Lancet Infect Dis 2004; 4(2): 112-124.
10. Oneschuk, op. cit. note 2;
11. White, op. cit. note 3;
12. Vitetta, op. cit. note 4;
13. Chen, op. cit. note 4.
14. White, op. cit. note 3;
15. J. Homsi, D. Walsh, R. Panta, R. Lagman, K.A. Nelson & D.L. Longworth. Infectious complications of advanced cancer. Supportive Care in Cancer 2000. 8(6): 487-492;
16. J. Pereira, S. Watanabe & G. Wolch. A retrospective review of the frequency of infections and patterns of antibiotic utilization on a palliative care unit. J Pain Symptom Manage 1998; 16(6): 374-381.
17. One notable exception to this is a study by Clayton et al. although the patients were not randomized or even entered into standardized treatment regimens. See J. Clayton, B. Fardell, J. Hutton-Potts, D. Webb & R. Chye. Parenteral antibiotics in a palliative care unit: prospective analysis of current practice. Palliat Med 2003; 17(1): 44-48.
18. This case does not constitute a single individual patient. It is an amalgamation of cases created by drawing on the various authors' clinical experiences in ethics consultation, infectious disease, palliative medicine, and oncology.
19. D.B. Hinshaw, T. Pawlik, A.C. Mosenthal, J.M. Civetta & J. Hallenbeck. When do we stop, and how do we do it? Medical futility and withdrawal of care. J Am Coll Surg 2003; 196(4): 621-651;
20. R. Lofmark & T. Nilstun. Conditions and consequences of medical futility - from a literature review to a clinical model. J Med Ethics 2002; 28(2): 115-119.
21. J. Groopman. 2004. The Anatomy of Hope. New York, NY. Random House;
22. E. Kodish & S. Post. Oncology and Hope 1994; 12: 1817-1822;
23. M. Miller. Phase 1 Cancer Trials: A Collusion of Misunderstanding. Hastings Center Report 2000; 30(4): 34-42.
24. A.L. Jennings, A.N. Davies, J.P.T. Higgins & K. Broadley. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database of Systematic Reviews 4, 2004.
25. M.T. Hecker, D.C. Aron, N.P. Patel, M.K. Lehmann & C.J. Donskey. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Archive Intern Med 2003; 163: 972-978;
26. M.A. Steinman, R. Gonzales, J.A. Linder & C.S. Landefeld. Changing use of antibiotics in community-based outpatient practice 1991-1999. Ann Intern Med 2003; 138: 525-533.
27. S. Chang, D.M. Siever, J.C. Hagerman, M.L. Boulton, E.C. Tenover, F.P. Dowries, S. Shah, J.T. Rudrik, G.R. Pupp, W.J. Brown, D. Cardo & S.K. Fridkin. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-1347;
28. C.J. Whitener, S.Y. Park, F.A. Browne, L.J. Parent, K. Julian, B. Bozdogan, P.C. Appelbaum, J. Chaitram, L.M. Weigel, J. Jernigan, L.K. McDougal, F.C. Tenover & S.K. Fridkin. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004; 38: 1049-1055.
29. A.J.J. Wood. When increased therapeutic benefit comes at increased cost. N Engl J Med 2002; 346(23): 1819-1821;
30. D. Schrag. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004; 351(4): 317-319.
31. A. Moss (for the Renal Physicians Association and the American Society of Nephrology Working Group). Shared Decision-making in Dialysis: A New Clinical Practice Guideline to Assist with Dialysis-Related Ethics Consultations. J Clinical Ethics 2001; 12(4): 406-414.
32. L.M. Cohen & M.J. Germain. Measuring quality of dying in end-stage renal disease. Semin Dial 2004; 17(5): 376-379.
33. S. Dalal & E. Bruera. Dehydration in cancer patients: to treat or not to treat. J Support Oncol 2004; 2(6): 467-479.
34. Oneschuk, op. cit. note 2, p. 28.